Singapore, Oct. 6 -- South Korea's Boryung Corporation has signed an asset purchase agreement with the global biopharma company Sanofi to acquire the cytotoxic anti-cancer drug Taxotere (docetaxel) across global territories, including domestic and international rights related to marketing, distribution, regulatory approvals, manufacturing, and trademarks.

The proposed purchase price is up to approximately 175 million euros (equivalent to around 287.8 billion KRW), inclusive of potential milestone payments worth 14 million euros.

Under the terms of the agreement, and subject to the obtaining of all regulatory approvals, Boryung will take over the entire Taxotere business in 19 countries, including Korea, Germany, Spain, and China as well...